NASDAQ:VKTX

Viking Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VKTX

*Your capital is at risk

$29.33

+0.0400 (+0.137%)

At Close: Jun 03, 2026

Viking Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -59.20. In total, the insiders bought 2.69M and sold 1.09M VKTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-59.20
● Buy	2.69M shares
● Sell	1.09M shares
67% Buy Activity Weak Positive Correlation
Buy Signal Low Confidence May 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -59.2. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Buy	Common Stock J-Other	Chen Hubert C Insider	Other	0 Value: $0
Jun 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Chen Hubert C Chief Medical Officer	Officer	190 000 Value: $5.94M
Mar 10, 2026 Buy	Common Stock, par value $0.00001 per share P-Purchase	Aubuchon Neil William Chief Commercial Officer	Officer	4 475 Value: $149.9K
Jan 12, 2026 Buy	Common Stock J-Other	Aubuchon Neil William Insider	Other	0 Value: $0
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Aubuchon Neil William Chief Commercial Officer	Officer	180 000 Value: $5.72M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Mancini Marianna Chief Operating Officer	C-Suite Officer	13 600 Value: $453.9K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Mancini Marianna Chief Operating Officer	C-Suite Officer	31 961 Value: $1.03M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Zante Greg Chief Financial Officer	C-Suite Officer	1 500 Value: $48.1K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Zante Greg Chief Financial Officer	C-Suite Officer	13 900 Value: $464.0K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Zante Greg Chief Financial Officer	C-Suite Officer	31 961 Value: $1.03M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Zante Greg Chief Financial Officer	C-Suite Officer	10 300 Value: $352.6K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Mancini Marianna Chief Operating Officer	C-Suite Officer	10 500 Value: $359.3K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Mancini Marianna Chief Operating Officer	C-Suite Officer	1 600 Value: $56.1K
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Lian Brian President & CEO	CEO / President	132 454 Value: $4.28M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Lian Brian President & CEO	CEO / President	53 279 Value: $1.78M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Lian Brian President & CEO	CEO / President	41 276 Value: $1.41M
Jan 05, 2026 Sell	Common Stock, par value $0.00001 per share S-Sale	Lian Brian President & CEO	CEO / President	6 400 Value: $224.4K
Jan 02, 2026 Buy	Common Stock, par value $0.00001 per share A-Award	Rouan Sarah Kathryn Director	Director	3 150 Value: $111.6K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Rouan Sarah Kathryn Director	Director	20 400 Value: $722.6K
Jan 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Foehr Matthew W Director	Director	16 000 Value: $53.3K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Foehr Matthew W Director	Director	20 400 Value: $722.6K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Rowland Charles A Jr Director	Director	20 400 Value: $722.6K
Jan 02, 2026 Buy	Common Stock, par value $0.00001 per share A-Award	Rowland Charles A Jr Director	Director	3 150 Value: $111.6K
Jan 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Macartney Lawson Director	Director	20 400 Value: $722.6K
Jan 02, 2026 Buy	Common Stock, par value $0.00001 per share A-Award	Mancini Marianna Chief Operating Officer	C-Suite Officer	32 049 Value: $1.14M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VIKING THERAPEUTICS

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also dev...

Read Full Profile Here